Adaptive immune systems in bacteria and archaea rely on small CRISPR-derived RNAs (crRNAs) to guide specialized nucleases to foreign nucleic acids. The activation of these nucleases is controlled by a series of molecular checkpoints that ensure precise cleavage of nucleic acid targets, while minimizing toxic off-target cleavage events. In this review, we highlight recent advances in understanding regulatory mechanisms responsible for controlling the activation of these nucleases and identify emerging regulatory themes conserved across diverse CRISPR systems.
Introduction
Nucleases that degrade DNA and RNA are indispensable for diverse biological functions [1] . To avoid toxicity associated with aberrant activity, nucleases are often controlled by substrate binding at (orthosteric), or away from (allosteric) the active site. Recent evidence suggests that CRISPR (Clustered Regularly Interspaced Short Palindromic Repeat)-associated (Cas) nucleases, which are essential components of adaptive immune systems that protect bacteria and archaea from infection by viruses and plasmids, rely on orthosteric and allosteric control [2, 3] . Presumably these regulatory mechanisms evolved to efficiently eliminate foreign DNA or RNA, while avoiding autoimmune reactions associated with destruction of the bacterial or archaeal genome. The programmable nature of CRISPR-associated nucleases (e.g., Cas9) has given rise to a powerful new method for genome engineering, and a comprehensive understanding of how these nucleases function is necessary for safe implementation [4] [5] [6] [7] .
CRISPR RNA-guided adaptive immune systems are structurally and functionally diverse, consisting of two Classes (1 and 2), six Types (I-VI), and more than nineteen subtypes distinguished by CRISPR repeat sequence and cas genes [2, [8] [9] [10] (Figure 1 ). Despite this diversity, all CRISPR systems rely on specialized nucleases to execute three stages of adaptive immunity; acquisition, CRISPR RNA biogenesis, and interference [2, 3] . During acquisition, a nuclease active integrase complex comprised of Cas1 and Cas2 proteins inserts foreign nucleic acid targets (about 20-40 nt in length) called 'protospacers' into the spacer-repeat array at the leader end of the CRISPR locus. CRISPR loci are transcribed, and Cas or RNAse III enzymes process these transcripts into libraries of small CRISPR-derived RNAs (crRNA). Each crRNA assembles with Cas proteins into surveillance complexes that use the crRNA to bind complementary DNA (Type I, II, V) or RNA (Type III, VI) ( Figure 1 ). Target binding induces conformational rearrangements within the surveillance complex that activate either cis-acting nuclease domains located within the complex, or a trans-acting nuclease that is recruited for destruction of bound targets.
Structures of Cas nucleases involved in spacer acquisition (e.g., Cas1) and crRNA biogenesis (e.g., Cas6), suggest substrate binding at the enzymatic active site (i.e., orthosteric) induces conformational rearrangements that regulate the nuclease [11] [12] [13] . In contrast, Cas nucleases involved in interference rely on a combination of orthosteric and allosteric activation mechanisms. Here we review the regulatory mechanisms that control Cas nucleases involved in interference.
Regulation of Class 2 Cas nucleases
Class 2 systems consist of three different Types (i.e., Type II, V, and VI) that encode single-subunit Cas nucleases [2, 8, 9] (Figure 2 ). The Type II (Cas9) systems gained considerable notoriety in 2012 and early 2013 when the programmable nature of these RNA-guided nucleases was exploited for precise cleavage of DNA in human cells (for a review of the primary literature, see [4] [5] [6] ). In the last five years, these nucleases have ushered in a new era of genome editing technologies that have considerable potential for applications in molecular medicine, industrial biotechnology, and agriculture.
Type II systems
The implementation of Type II systems for genome editing applications requires a fundamental understanding of how these RNA-guided nucleases assemble, bind (Cpf1) (C2c1) (C2c3) (C2c2)
non-complementary strand non-complementary strand
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Class 2 Nuclease activation mechanisms.
(a) Activation of the Type II Cas9 nuclease (grey with red outline) relies on several regulatory checkpoints. Cas9 adopts a bi-lobed structure that consists of a nuclease-lobe (Nuc lobe) and an alpha-helical recognition lobe (Rec lobe). Single-guide-RNA loading causes a conformational rearrangement in the Rec lobe. To bind duplex DNA, a PAM motif (dark red) is recognized followed by 3 0 seed complementation. Directional unwinding of the duplex to the PAM-distal side of the guide induces a conformational rearrangement of two peptide linkers (L1 and L2 colored blue and orange) that stabilize the active conformation of the HNH and RuvC nuclease domains (colored red) to make a blunt-end cut in duplex DNA. (b) Type V nucleases (Cas12a, Cas12b, and Cas12c; also known as Cpf1, C2c1, and C2c3) also adopt a bi-lobed architecture, are loaded with an RNA-guide and use PAM and seed recognition to initiate target binding with DNA. However, the DNA cleavage mechanisms may involve the RuvC domain and Nuc domain, or just the RuvC domain. (c) Like Type II and V, the Type VI (Cas13, also known as C2c2) proteins adopt a bilobed architecture and are programmed with an RNA-guide. Type VI nucleases bind RNA with a central seed within the RNA-guide, and an adjacent sequence called the PFS (Protospacer Flanking Site) plays a role in nuclease activation.
to double-stranded DNA (dsDNA), and then cleave both strands of the dsDNA target. Initial biochemical work on the Cas9 ribonucleoprotein from Streptococcus pyogenes showed that the crRNA base-paired to a trans-activating tracrRNA, and that these two RNAs could be fused into a single-guide RNA (sgRNA) capable of directing the Cas9 nuclease to a complementary DNA [14, 15] . Subsequent structural and biochemical studies demonstrated that Cas9 is a dynamic enzyme, and that target cleavage requires sequential completion of multiple regulatory checkpoints.
Cas9 adopts a bi-lobed architecture in which two adjacent nuclease domains (RuvC and HNH) reside within the nuclease lobe (NUC lobe), and an alpha-helical lobe (also known as the recognition or REC lobe) interacts with the guide RNA-target DNA heteroduplex [16 ,17 ,18 ,19 ,20 ,21 ]. In the absence of RNA, Cas9 adopts a nuclease-inactive conformation, which undergoes a dramatic rearrangement upon binding the guide RNA [16 ] (Figure 2a ). Cas9 relies on base-pairing between the crRNA guide and DNA targets, but single-molecule experiments performed using Cas9 from Streptococcus pyogenes showed that Cas9 must first recognize a tri-nucleotide motif called a PAM (Protospacer Adjacent Motif) located next to the DNA target sequence [22 ] . In addition to PAM recognition, high-affinity binding requires precise complementarity between the DNA target and a PAM-proximal 'seed sequence' followed by directional unwinding of the DNA from the seed to the PAM-distal end of the target [23 ] (Figure 2a ). Chromatin immunoprecipitation followed by sequencing (ChIPseq), revealed that as many as 15 mismatches are allowed outside of the seed sequence for stable binding, but incomplete RNA-DNA hybrids are often not cleaved by Cas9 [24] [25] [26] .
Initial structures of DNA-bound Cas9 could not explain why stable binding and incomplete R-loop formation fail to activate Cas9 cleavage. In these structures, the active site of the HNH nuclease domain is 30 Å away from the scissile phosphate of the target DNA strand [17 ,18 ,27 ] (Figure 2a ), suggesting that a major conformational rearrangement was necessary to activate Cas9-mediated DNA cleavage. To test this hypothesis and clarify the substrate features required for Cas9 activation, Forster Resonance Energy Transfer (FRET)-based assays were used to measure conformational changes in the HNH domain upon binding to perfectly complementary and mismatched DNA targets [28 ] . This work revealed that the HNH nuclease domain adopts an inactive conformation on mismatched DNA substrates that are stably bound by Cas9, explaining why off-target DNA binding events do not always lead to off-target DNA cleavage. Full complementarity between target DNA and the crRNA guide drives conformational changes in the HNH domain that trigger target-strand cleavage, and allosterically activates cleavage of the non-complementary strand by the RuvC domain, ensuring concerted production of double-strand breaks [28 ] .
A recent structure of Cas9 bound to a long dsDNA substrate provides a structural basis for the concerted activation of the Cas9 nuclease domains [29 ] (Figure 2 ). As observed in all other Cas9 structures, the HNH domain is inserted between motifs II and III in the RuvC domain, and is connected to these motifs by two peptide linkers, L1 and L2. Comparison with previous Cas9 structures reveals that L1 and L2 undergo extensive rearrangement after binding a dsDNA-target. L1 interacts with the PAM-distal side of the RNA-DNA hybrid, while a conserved phenylalanine on L2 stacks with the fourth nucleobase of the protospacer on the non-complementary strand. These interactions stabilize a 180 rotation of the HNH domain and position the active site in proximity to the scissile phosphate of the complementary strand. Additionally, these rearrangements position the scissile phosphate of the non-complementary strand into the active site of the RuvC nuclease. To avoid steric clashes, these large conformational rearrangements can only be achieved if both L1 and L2 move in concert, which explains why HNH and RuvC activation is coupled. Cas9 nucleases from organisms other than S. pyogenes share a similar HNH and RuvC domain linkage, suggesting this concerted activation mechanism may be conserved across all Cas9 enzymes [16 ,19 ,20 ,21 ].
Type V systems
Like Cas9, the Type V enzymes -Cas12a, Cas12b, and Cas12c; also known as Cpf1, C2c1, and C2c3 -contain a putative nuclease domain (Nuc) inserted between motifs II and III of a RuvC domain [9, [30] [31] [32] [33] [34] [35] . Point mutations in the Nuc domain of Cas12a (Cpf1) inhibited cleavage of the complementary strand, while mutations in the RuvC active site disrupted cleavage of both strands [31] . These data suggested RuvC-mediated cleavage of the non-complementary strand is a pre-requisite for cleavage of the complementary strand by the Nuc domain. However, a structure of Cas12b (C2c1) bound to a long singlestranded DNA suggests the RuvC nuclease may be responsible for cleaving both strands of the DNA in sequential order [34] . Indeed, a recent study of Cas12a provides biochemical evidence that a single active site within the RuvC domain cleaves both DNA strands using the same catalytic mechanism, and that activation of this nuclease function requires substantial conformational rearrangements to unblock the previously occluded active site [36] . While it appears that Cas12 enzymes recognize DNA targets in a distinct way from Cas9, both enzyme families have evolved mechanisms to sequester the active sites in their nuclease domains until RNA-DNA heteroduplex formation triggers activation.
Type VI systems
Unlike most Class 2 systems, which target dsDNA, the Type VI Cas nucleases (Cas13, also known as C2c2) bind and cleave ssRNA using two HEPN (Higher Eukaryote and Prokaryote Nucleotide-binding) domains [9, [37] [38] [39] (Figure 2b ). The HEPN RNase domains are activated by ssRNA base-pairing with the crRNA guide, but nuclease activity is suppressed if complementarity extends beyond the guide and into the repeat-derived portion of the crRNA [37] . Complementarity to the repeat-derived sequence of the crRNA may explain the inhibition of Cas13 (C2c2) nuclease activity, similar to regulation of DNase activity in Type III systems (see below). Notably, unlike other Class 2 systems, RNA binding by Cas13 activates a non-sequence specific and trans-acting RNase activity [37, 38] ; a property which has recently been harnessed for sensitive RNA and DNA diagnostics [40] . Thus, target-induced conformational rearrangements are required to activate the promiscuous HEPN nuclease domains. While recent structures have shed light on Cas13 conformational changes that occur upon crRNA binding [39] , further structural and biophysical studies are necessary to fully understand the conformational rearrangements that occur upon target RNA binding and the mechanism of RNA cleavage in trans.
Regulation of Class 1 nucleases that are essential for interference.
Class 1 CRISPR systems are phylogenetically and functionally diverse, but a unifying feature of these systems is that they all rely on multi-subunit crRNA-guided surveillance complexes for detection of invading nucleic acids [8, 41] . Class 1 systems consist of two well-studied Types (Type I and III), and a recently identified Type IV system that has not been experimentally tested and is beyond the scope of this review.
Type I systems
Phylogenetic studies have divided Type I systems into seven sub-types, I-A to I-F and I-U [8] . All Type I CRISPR systems rely on multi-subunit surveillance complexes for crRNA-guided detection of dsDNA targets, and a Cas3 nuclease/helicase that is responsible for target degradation.
Foreign DNA detection by the Type I-E system in Escherichia coli relies on a large crRNA-guided complex called Cascade (CRISPR-associated complex for antiviral defense) [42, 43] . Cascade searches for targets by first localizing to PAM sequences, which are recognized by the Cas8e subunit (also called Cse1) [23 ,44 ,45 ,46] . PAM detection destabilizes the target duplex and facilitates crRNA-guided sampling of the PAM-proximal DNA seed sequence [47] . Complementarity between the crRNA-guide and the seed leads to directional unwinding of the DNA duplex that proceeds away from the PAM and triggers a conformational change in Cascade Cascade elicits two distinct immune responses upon target binding: interference or priming (Figure 3 ). During interference, the Cas8e subunit adopts a 'closed' conformation capable of recruiting a nuclease active Cas3, which processively degrades the target DNA [44 ,50,51 ,57-59] . However, strict sequence requirements present a potential weakness in the immune system, because mutations in the PAM, seed, or specific positions of the protospacer, allow viruses to escape CRISPR-Cas immunity [47, 60, 61] . Bacteria with Type I immune systems can restore immunity against PAM or protospacer 'escape' mutants using a positive feedback loop that rapidly updates the CRISPR locus with new spacers derived from the phage or plasmid genome [61] [62] [63] [64] . This process of rapid acquisition, called 'priming', requires a target that is partially complementary to the crRNA-guide, Cas3, and two proteins that are essential for adaptation (i.e., Cas1 and Cas2) [62, 65] .
Mutated targets that elicit a priming response correspond to an 'open' conformation of the Cas8e subunit, which does not effectively recruit nuclease active Cas3 [44 ,51 ,52] (Figure 3 ). However, in the presence of Cas1 and Cas2, Cascade bound to a priming target efficiently recruits nuclease-repressed Cas3 [44 ] . Recent structural and biochemical studies performed using the Type I-F immune system from Pseudomonas aeruginosa, in which Cas2 and Cas3 are fused into a single polypeptide (Cas2/3), indicated that Cas1 and Cas2/3 form a complex, and that Cas1 represses Cas2/3 nuclease activity until activated by the target bound surveillance complex [66] .
Collectively, these results suggest that the conformational state of Cascade recruits a nuclease active Cas3 for direct degradation (interference) or a nuclease repressed Cas1-2/3 complex for rapid adaptation (priming) [44 ] . However, in both instances Cas3 cleavage products are precursors for CRISPR adaptation [67 ] , suggesting that priming targets do elicit some level of Cas3 nuclease activity and that primed adaptation also takes place during the interference response. It is clear Cas1, 2, and 3 work together to generate and integrate new sequences into CRISPR loci, but the mechanism of allosteric regulation of Cas3 activity by the conformational state of Cascade remains poorly understood.
Type III systems
Like Type I systems, the Type III systems also rely on large multi-subunit crRNA-guided surveillance complexes that are divided into sub-types (i.e., Type III-A-III-D) [8] . Initially these subtypes were functionally divided into either DNA or RNA targeting immune systems. However, a series of recent experiments revealed a sophisticated mechanism that explains how crRNA-guided binding to complementary RNA allosterically activates a non-sequence specific DNase activity (Figure 3 ) [68] . This model reconciles earlier distinctions between RNA or DNA targeting and reveals that Type III systems cleave both RNA and DNA targets.
The RNase and DNase active sites in Type III complexes are spatially separated, functionally integrated, and temporally controlled. RNA binding drives a conformational rearrangement that allosterically activates nonsequence-specific DNase activity in the Cas10 subunit [69,70 ,71 ,72 ,73 ,74 ,75 ] . The RNA target is cleaved in regular 6-nt intervals and structures of Type III complexes have identified residues in the backbone (Cas7-family) and belly subunits that are necessary for RNA cleavage [41, 68, 76] . According to the current model, periodic cleavage of the RNA target, leads to dissociation of the RNA fragments, which restores the complex to a DNase inactive state [68,70 ,71 ,72 ].
In addition to complementarity between the crRNAguide and the RNA protospacer, sequence 3 0 of the protospacer regulates DNase activity. Complementarity between the crRNA and the RNA target that extends beyond the guide and into the 5 0 -repeat of the crRNA inhibits DNase activation in all Type III systems [70 ,71 ,72 ,73 ,74 ,75 ,77] , but requirements for DNase activation seem to vary between systems. In Thermotoga maritima, the DNase function is activated by protospacers lacking flanking sequence, suggesting complementation between the crRNA-guide and RNA target is the only signal necessary for DNase activation and base pairing with the 5 0 -repeat is inhibitory [71 ] . However, in several other systems, hybridization with the protospacer sequence alone is not sufficient for DNase activation. In these systems, the DNase remains inactive unless a non-complementary sequence extends from the protospacer into the 5 0 -repeat [72 ,73 ,75 ] , and in some systems (e.g., Type III-B Cmr system in P. furiosus) this 3 0 non-complementary RNA sequence must meet specific sequence requirements [70 ] . The mechanistic distinctions between these systems and the precise role of the 3 0 RNA in controlling DNase activation awaits structural studies of Type III complexes bound to RNAs with 3 0 -flanking sequence.
Perspective CRISPR-associated nucleases are phylogenetically and functionally diverse, yet common regulatory themes are beginning to emerge. All CRISPR systems that target DNA rely on protein mediated PAM recognition and crRNA-guided recognition of the protospacer. However, binding does not necessarily result in target cleavage. Recent data indicates that different PAM and protospacer combinations result in distinct conformational states that regulate nuclease activity. These new insights are revealing additional layers of sophistication in prokaryotic adaptive immune responses, and understanding how target selection impacts the activity of these nucleases will have important implications for applications in genome editing.
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